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Abstract. Renal osteodystrophy and osteoporosis are related to chronic renal disease. In the present research and 
clinical dilemmas, indications have been proposed concerning the possible application of bisphosphonates in patients 
suffering from renal insufficiency. The aim of the study is to present a patient with disturbed renal function who was 
treated with parenteral bisphosphonates. The patient is a 56-year old male who was receiving hemodialysis for 29 
years. In order to estimate risk for further bone fractures and to evaluate possible indication for intravenous 
bisphosphonates a bone mineral densitometry was performed, as well as transiliac biopsy with histological examination 
of the bone. The etiology of bone fractures in renal patients is multifactorial and cannot be fully explained only with the 
aid of pathohistological examination. After the thorough diagnostics, it could be possible to apply bisphosphonates in the 
treatment of patients with renal osteodystrophy on chronic hemodialysis or peritoneal dialysis. 




Bisphosphonates are inhibitors of osteoclastic bone re-
sorption and are commonly used for the treatment of os-
teoporosis, bone resorption and hypercalcemia of differ-
ent etiology [1]. Because of the adverse side-effects 
bisphosphonates are not used in the treatment of patients 
with terminal renal failure [2]. They are studied for possi-
ble use in the treatment of renal osteodystrophy and have 
not been approved for use yet in patients with renal fail-
ure [3]. Approximately 80% of the bisphosphonate is 
eliminated by the kidneys, with the remaining 20% taken 
up by the bone. Because of the risk of accumulation, ele-
vated serum creatinine is listed in the manufacturers’ lit-
erature as a contraindication to bisphosphonates use [4]. 
However, they have been safely used in dialysis patients 
and after renal transplantation for the treatment of high 
turnover bone disease, as well as vascular calcification 
and osteoporosis [5].  
Case Report 
Among 120 peritoneal dialysis (PD) patients, the study 
describes a 56-year old male who had been on hemodi-
alysis (HD) since 1977 and started peritoneal dialysis in 
2001. In 2006 he had an episode of syncope when he fell 
down and got left femoral neck fractures with low 
mechanical impact. Dual energy x-ray absorptiometry of 
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the spine (L1–L4) was used to measure bone mineral 
density (BMD) in range of osteoporosis: 0,878 g/cm², T 
score -2,5. Furthermore, BMD was also measured in left 
femur in a range osteoporosis: total left femur BMD 
0,631 g/cm², T score -3,1. We have been using cyclically 
one intravenous infusion of clodronate 300 mg/weekly 
during 6 months. After 6 months of therapy bone 
densitometry was repeated and it revealed deterioration in 
BMD of the spine (L1–L4) 0,847g/cm² with T score -2.78; 
on left femur BMD (total femur was 0,592 g/cm², T score -
3,4). The therapy was terminated although the desired 
effect of the inhibition of osteoclast activity was not 
achieved due to the inability to determine the cumulative 
 
Fig. 1. Bone biopsy; hematoxylin and eosin, original 
magnification 200. H & E staining of a biopsy 
sample for general histology (MB, mineralized 
bone; M, marrow). Scale bar = 10 m 
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dose and because of the concern of possible side effects of 
the medication [6]. In order to exclude low bone turnover 
iliac biopsy was performed which excluded other 
mechanisms except osteoporosis.  
Discussion 
In the present research, indications have been proposed 
concerning the possible application of bisphosphonates in 
patients suffering from renal insufficiency The national 
guidelines have no recommendations on the treatment of 
renal rapid turnover osteodistrophy and osteoporosis us-
ing bisphosphonates in renal patients [7]. Previous clini-
cal studies have shown that bisphosphonates can be 
safely used in preventing complications and preserving 
bone mass in a population of renal patients. Bisphospho-
nates can be used with caution and in especially treatment 
of malignant hypercalciemia [8]. The dose of drug, the 
length of treatment (delayed complications) should be 
adapted to dialysis modality and residual renal function [9]. 
Conclusion 
There is no clear beneficial effect of bisphosphonate 
treatment that outweighs possible side-effects in patients 
with renal failure at the moment. Positive result can be 
expected, but we need more clinical data regarding efficacy 
and safety of bisphosphonates in dialysis patients. 
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Fig. 2. Bone marrow medulla; hematoxylin and eosin, 
original magnification 200. H & E staining of a 
biopsy sample the ratio of cells to fat about 50% 
(T, trabeculae; M, marrow). Scale bar = 10 m 
 
Fig. 3. X –ray; anteroposterior radiograph of the hands. 
Subperiosteal bone resorption is visible.  
